Option chain shows key data for Innovent Biologics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Innovent Biologics.

Innovent Biologics (OTC:IVBIY) Stock, Option Chain

Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has 12 commercialized oncology products and three commercialized nononcology products as of March 2025. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.

Biotech

News

Penny Stocks

Health Care

General

IVBIY

INNOVENT BIOLOGICS INC by Innovent Biologics Inc.

IVBXF

FDA Rejects Lilly&#39;s Sintilimab/Chemo Combo Therapy In First-Line Lung Cancer Setting

The FDA advisory committee voted against the full approval of Eli Lilly And Co&#39;s (NYSE: LLY) lung cancer treatment over concerns that the clinical trial was conducted only in China and that its results did not apply to U.S. patients.

FDA AdComm Votes Against Lilly&#39;s Lung Cancer Drug, Sintilimab

Contracts

Innovent Biologics, UNION therapeutics Ink Licensing Pact For Inflammatory Dermatology Candidate

INNOVENT BIOLGCS UNSP/ADR by Innovent Biologics Inc.

Innovent Biologics Inc

Commodities

Press Releases

Innovent Released 2024 ESG Report, Underscoring Commitment to Sustainable Development and Global Innovation

Phase 3 Clinical Study of Mazdutide in Chinese Adults with Overweight or Obesity (GLORY-1) Published in The New England Journal of Medicine (NEJM)

Innovent Announces a Phase 3 Study of Picankibart (Anti-IL-23p19 Antibody) Completes First Participant Dosing, Exploring Biologics Switching Treatment for Psoriasis Patients with Prior Inadequate Response to Anti-IL-17 Antibodies

ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α -bias Bispecific Antibody Fusion Protein) from Phase 1 and 2 Clinical Studies on Immunotherapy-treated Advanced Malignant Melanoma

2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Date of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from Phase 1 Clinical Studies in Advanced Colorectal Cancer

2025 ASCO Presentation: Innovent Biologics Announces Updated Data of IBI354 (Novel anti-HER2 ADC) From the Phase 1/2 Clinical Study in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors

ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI343 (Novel Anti-CLDN18.2 ADC) From the Phase 1 Clinical Study in Patients with Advanced Pancreatic Cancer

2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from the Phase 1 PoC Clinical Study in Advanced Non-small Cell Lung Cancer

Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell Carcinoma

Innovent's IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Receives Second NMPA Breakthrough Therapy Designation for  Immuno-resistant Squamous Non-Small Cell Lung Cancer

Innovent Biologics

Comments

Innovent Biologics

Innovent Biologics (IVBIY) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell